Perimenopause Misdiagnosis: Why 1 in 3 Women Get the Wrong Answer First

DEFINITION

Diagnostic delay in perimenopause

The time between symptom onset and correct identification of perimenopause as the cause. Research shows 74% of women experience symptoms for more than one year before receiving adequate help, with many cycling through multiple incorrect diagnoses first.

DEFINITION

Epistemic injustice in healthcare

When a patient's report of their own experience is systematically discounted or reinterpreted. In perimenopause, this occurs when providers attribute reported symptoms to psychological causes without investigating hormonal explanations, particularly for cognitive and mood symptoms.

The Scale of the Problem

One in three. That is the misdiagnosis rate for perimenopause in the US according to a 2023 Kindra/Harris Poll survey of women aged 45 to 54. A third of women received a wrong diagnosis before anyone identified perimenopause as the cause of their symptoms.

These were women with symptoms consistent with perimenopause who were told they had something else — often for months or years before anyone got it right.

Separate research from Newson Health in the UK found that 74% of women experienced symptoms for more than one year before receiving adequate help. The diagnostic delay is not days or weeks. It is measured in years.

What Perimenopause Gets Misdiagnosed As

Perimenopause produces symptoms across nearly every body system. Many of those symptoms have other plausible explanations when you look at them one at a time.

Anxiety and depression. The most common misdiagnosis. Fluctuating estrogen directly affects serotonin and GABA systems, producing anxiety and mood changes through hormonal mechanisms. But because the presenting complaint is anxiety, and because anxiety disorders are well-understood in medical training, the hormonal contribution is often overlooked entirely.

Thyroid dysfunction. Fatigue, weight changes, temperature sensitivity, mood changes, and brain fog all appear in both perimenopause and thyroid disorders. A thyroid panel is easy to order and often comes back normal, at which point the investigation may stop rather than continuing to perimenopause.

IBS and digestive disorders. Hormonal fluctuations affect gut motility and the gut-brain axis. Women presenting with new-onset bloating, irregular bowel patterns, and abdominal discomfort in their 40s may receive an IBS diagnosis without any inquiry into their menstrual cycle status.

Chronic fatigue syndrome and fibromyalgia. The combination of fatigue, widespread pain, cognitive difficulties, and sleep disruption maps onto both conditions. When a woman in her 40s presents with these symptoms, CFS or fibromyalgia may be considered before perimenopause is.

Why It Happens: The Training Gap

The misdiagnosis pattern has a specific explanation. A 2023 study by Allen and colleagues, published in Menopause, found that 68.7% of US OB/GYN residency programs have no dedicated menopause curriculum. The physicians most likely to see perimenopausal patients were never trained to identify the condition.

The system has not prioritized menopause education. A provider who finished residency without menopause training defaults to the diagnostic frameworks they were taught: psychiatric, endocrine, rheumatologic. They may not consider perimenopause because nobody taught them to.

The result is predictable. A 2023 study published in Maturitas found that 38% of women were offered antidepressants rather than HRT as their first treatment for perimenopause symptoms. Antidepressants address the symptom presentation the provider recognizes. HRT addresses the underlying hormonal cause the provider was not trained to investigate.

The Antidepressant Default

The 38% antidepressant-first figure deserves its own section because it is the most consequential pattern in the data.

SSRIs and SNRIs can be appropriate for perimenopausal women with comorbid depression or anxiety disorders that exist independently of hormonal changes. They are also appropriate when HRT is contraindicated. NICE guidelines in the UK are explicit that antidepressants should not be offered as first-line treatment for menopausal mood symptoms when HRT is an option.

The problem is not that antidepressants get prescribed. It is that they get prescribed instead of investigating the hormonal explanation, because the provider’s training points toward psychiatric diagnosis, not hormonal transition.

A woman on an SSRI for what is actually hormonally-driven anxiety may experience partial improvement (SSRIs do affect the symptoms) while the underlying cause remains unaddressed. Her hot flashes, sleep disruption, and cognitive changes continue because they were never the target of treatment.

How Tracking Changes the Equation

Structured symptom tracking does not guarantee a correct diagnosis. But it shifts the odds.

When you bring four to six weeks of daily data showing that anxiety spikes correlate with cycle phase changes, that brain fog and hot flashes co-occur, and that sleep disruption follows a pattern rather than appearing random, the hormonal explanation becomes visible in a way that a verbal account in a 15-minute appointment cannot achieve.

Tracking data is most useful for symptoms that get blamed on something else. Cognitive changes documented daily with severity ratings and functional impact are harder to wave away as “just stress” than a verbal mention of “feeling foggy sometimes.” Mood changes that map to cycle patterns suggest hormonal contribution more clearly than a PHQ-9 score taken at a single point in time.

A 2024 Climacteric study found that physicians under-report cognitive difficulties by 26.9% and mood symptoms by 22.3% compared to what patients actually report. The gap between what you experience and what gets written in your chart is where misdiagnosis lives. Your own tracking data closes it.

What to Do If You Have Been Dismissed

If you are reading this because you suspect a previous diagnosis missed perimenopause, here is a practical path forward.

Start tracking now. Use a tool that captures the full symptom range: vasomotor, cognitive, mood, sleep, musculoskeletal. Daily entries. Severity ratings. Notes on functional impact. Four to six weeks minimum.

Do not stop current treatment without medical guidance. If you are on antidepressants or other medication, continue as prescribed while you build your symptom record. The goal is additional information, not abrupt treatment changes.

Request a specific conversation. At your next appointment, bring the tracking data and ask directly: “Given these symptom patterns, has perimenopause been considered as a contributing factor?” This is a different question from “I think I have perimenopause,” because it invites clinical assessment rather than requiring the provider to validate your self-diagnosis.

Seek specialized care if needed. The Menopause Society maintains a directory of certified practitioners. If your current provider has not engaged meaningfully with the hormonal explanation after reviewing your data, a specialist referral is appropriate. Your tracking data comes with you.

We built Horiva specifically for this situation. When 33% of women get the wrong answer first, the tool that helps you build the right evidence matters. On-device storage means your symptom data stays yours, and exportable reports mean it travels to any provider you choose.